# A Trial to See if the Combination of Fianlimab With Cemiplimab Works Better Than Pembrolizumab for Preventing or Delaying Melanoma From Coming Back Af

Source: https://onco.cc/trials/nct05608291/  
OnCo record `nct05608291` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Fianlimab, Cemiplimab, Pembrolizumab in melanoma, run by Regeneron Pharmaceuticals, active and no longer recruiting.

## Summary

A Trial to See if the Combination of Fianlimab With Cemiplimab Works Better Than Pembrolizumab for Preventing or Delaying Melanoma From Coming Back After it Has Been Removed With Surgery is a phase 3 interventional study registered as NCT05608291 by Regeneron Pharmaceuticals, with 1564 participants enrolled, started 2023-01-16 and due to reach its primary completion in 2026-07-27. Interventions recorded: Fianlimab, Cemiplimab, Pembrolizumab, Placebo. Conditions listed: Melanoma. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT05608291
- Phase: 3
- Setting: A Phase 3 Trial of Fianlimab (Anti-LAG-3) and Cemiplimab Versus Pembrolizumab in the Adjuvant Setting in Patients With Completely Resected High-risk Melanoma
- Sponsor: Regeneron Pharmaceuticals
- Enrolled: 1564

## Sources

- ClinicalTrials.gov NCT05608291: https://clinicaltrials.gov/study/NCT05608291

## Connected records

- cancers: [Melanoma](https://onco.cc/cancers/melanoma/)
- drugs: [Cemiplimab](https://onco.cc/drugs/cemiplimab/), [Fianlimab](https://onco.cc/drugs/fianlimab/), [Pembrolizumab](https://onco.cc/drugs/pembrolizumab/)
- companies: [Regeneron](https://onco.cc/companies/regeneron/)

---
JSON: https://onco.cc/api/v1/entities/nct05608291.json